Previous 10 | Next 10 |
Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Th...
Vera Therapeutics (NASDAQ:VERA) commenced a public offering to issue and sell 4M class A shares. VERA expects to grant the underwriters a 30-day option to purchase up to an additional 600K class A shares. For further details see: Vera Therapeutics announces public offering of 4M class A...
BRISBANE, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has commenced ...
BRISBANE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced plans to initiate a Phase 3 clinical...
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD,...
Vera (NASDAQ:VERA) has more than given back gains it made on Friday following the acquisition of a monoclonal antibody candidate from Pfizer (NYSE:PFE), closing down 18%. The deal with Pfizer is for MAU868, a first-in-class monoclonal antibody to treat BK virus, the leading cause of kidn...
Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of transplant loss and transplant-associated morbidity BRISBANE, Calif., Dec....
BRISBANE, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Kimball...
Gainers: Insignia Systems (NASDAQ:ISIG) +106%. Energy Focus (NASDAQ:EFOI) +65%. Virpax (NASDAQ:VRPX) +26%. Aziyo (NASDAQ:AZYO) +26%. Digital World Acquisition (NASDAQ:DWACU) +20%. Digital World Acquisition (NASDAQ:DWAC) +20%. RLX Technology (NYSE:RLX) +20%. The Lovesac (NASDAQ:LOVE) +19%. Pho...
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Vera Therapeutics Inc. Company Name:
VERA Stock Symbol:
NASDAQ Market:
Vera Therapeutics Inc. Website:
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L....
2024-06-15 11:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy ...